Drug pricing, patent losses and deals: Here's what pharma execs see ahead in the industry
Big pharma is grappling with new drug pricing deals and roughly $300 billion in potential lost revenue from patent expirations of blockbuster drugs.
TL;DR
- Drug pricing deals, particularly Trump's 'most-favored-nation' policy, are seen as reducing uncertainty with a modest business impact.
- Companies like Sanofi, AstraZeneca, and Pfizer are assessing the financial implications of these drug pricing agreements.
- Major drugmakers are actively pursuing acquisitions and collaborations to compensate for an estimated $300 billion in potential revenue loss from expiring patents.
- Merck and Bristol Myers Squibb are preparing for patent expirations of blockbuster drugs like Keytruda and Eliquis, respectively, by focusing on new product development and business development.
- Novo Nordisk faces patent expirations for semaglutide in international markets and is active in business development to complement its pipeline.
- Concerns were raised by Pfizer CEO Albert Bourla regarding the Trump administration's changes to U.S. immunization policy, citing a lack of scientific merit and potential public health consequences.
- Sanofi CEO Paul Hudson acknowledged discussions with Robert F. Kennedy Jr. regarding vaccine evidence.